Latest Content

Partial response to bridging therapy before cilta-cel was associated with improved PFS and OS outcomes in relapsed/refractory multiple myeloma.

From hedgehog pathway mutations to next-generation sequencing, Vernon Sondak, MD, outlines a practical framework for complex BCC and CSCC workup.

Experts recap of the most pivotal lung cancer data to surface at the 2026 ASCO Annual Meeting.

Ficerafusp alfa plus pembrolizumab generated a 54% ORR and 21.7-month median DOR in first-line HPV-negative recurrent or metastatic HNSCC.

EPCORE FL-1 showed that epcoritamab/lenalidomide/rituximab yielded superior efficacy vs lenalidomide/rituximab across follicular lymphoma populations.

Azacitidine plus venetoclax and ivosidenib produced robust responses and induced high rates of MRD negativity in IDH1-mutated newly diagnosed AML.

Baseline ctDNA positivity was associated with inferior DFS regardless of treatment arm in the phase 3 KEYNOTE-564 trial.

Alexander Kutikov, MD, FACS, discusses the role of focal therapy in RCC management.

The in vivo CAR T-cell therapy KLN-1010 produced deep MRD-negative responses in relapsed/refractory multiple myeloma.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

The research offers an early view into challenges that health systems across the globe will likely face as extreme heat becomes more common.

The FDA has accepted for review an sBLA for adjuvant atezolizumab plus chemotherapy in stage III dMMR/MSI-H colon cancer.

Marwan G. Fakih, MD, discusses how updated OS data from POD1UM-303 cement frontline retifanlimab plus chemotherapy as the standard of care in advanced SCAC.